Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Merge symbols : Nrxp save search
NRx Pharmaceuticals Submits Emergency Use Authorization Application to US FDA for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
NRXP 1 d | $3.065 1.49% 210K
|
Manufacturing
|
| O: 1.52%
H: 0.0%
C: 0.0%
covid-19 zyesami treatment fda aviptadil als risk application covid media authorization merge emergency use authorization
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
Published: 2021-11-05 (Crawled : 10:00) - biospace.com/
NRXP 1 d | $3.065 1.49% 210K
|
Manufacturing
|
| O: -39.12%
H: 30.27%
C: 17.7%
covid fda aviptadil zyesami collaboration respiratory merge emergency use authorization
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
Published: 2021-07-28 (Crawled : 09:00) - biospace.com/
NRXP 1 d | $3.065 1.49% 210K
|
Manufacturing
|
| O: -3.24%
H: 8.08%
C: -6.18%
collaboration merge authorized aviptadil emergency use authorization
NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
Published: 2021-07-27 (Crawled : 16:00) - prnewswire.com
NRXP 1 d | $3.065 1.49% 210K
|
Manufacturing
|
| O: -13.59%
H: 38.64%
C: 10.84%
merge authorized aviptadil emergency use authorization
NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia
Published: 2021-07-06 (Crawled : 14:00) - biospace.com/
NRXP 1 d | $3.065 1.49% 210K
|
Manufacturing
|
| O: 0.42%
H: 2.17%
C: -8.42%
phase 2 phase 2/3 trial merge aviptadil train
NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure
Published: 2021-06-01 (Crawled : 12:00) - biospace.com/
NRXP 1 d | $3.065 1.49% 210K
|
Manufacturing
|
| O: 6.36%
H: 0.0%
C: -6.92%
covid food positive results positive results respiratory drug merge authorized aviptadil emergency use authorization
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.